|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Fixed-maturity securities, available for sale, at fair value (amortized cost: $4,736,687, allowance for credit losses: $55 – 2026; $4,382,725 and $29 – 2025) | ||||||||||||||||||||
| Equity securities, at fair value (cost: $625,689 – 2026; $482,926 – 2025) | ||||||||||||||||||||
| Real Estate Investments, Net | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and Cash Equivalent | ||||||||||||||||||||
| Investment income due and accrued | ||||||||||||||||||||
| Premium Receivable, Allowance for Credit Loss | ||||||||||||||||||||
| Premiums and fees receivable, net of allowance for credit losses of $31,779 – 2026; $27,328 – 2025 | ||||||||||||||||||||
| Reinsurance recoverables, net | ||||||||||||||||||||
| Ceded unearned premiums | ||||||||||||||||||||
| Deferred policy acquisition costs, net of ceding commissions | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Deferred Income Tax Assets, Net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Reserves for unpaid losses and loss adjustment expenses | ||||||||||||||||||||
| Unearned premiums | ||||||||||||||||||||
| Payable to reinsurers | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Debt | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Common stock, shares issued (in shares) | ||||||||||||||||||||
| Common stock, shares outstanding (in shares) | ||||||||||||||||||||
| Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest | ||||||||||||||||||||
| Stockholders' Equity | ||||||||||||||||||||
| Common stock, $0.01 par value, 400,000,000 shares authorized, 23,500,708 and 22,509,945 shares issued and outstanding at September 30, 2026; 23,380,413 and 23,145,751 shares issued and outstanding at December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury Stock, Common, Shares | ||||||||||||||||||||
| Treasury Stock, Value | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
| Common stock, par value (in dollars per share) | ||||||||||||||||||||
| Common stock, shares authorized (in shares) | ||||||||||||||||||||
Loading...
